Rochester and Albany launch new Center of Excellence in RNA research
The joint venture between the University of Rochester and University at Albany will drive economic development through research and training.
Lynne Maquat awarded 2021 Wolf Prize in Medicine
Maquat, the founding director of the University’s Center for RNA Biology, was selected for “fundamental discoveries in RNA biology that have the potential to better human lives.”
Study offers new insights into fragile X syndrome
A Medical Center study offers insight into the molecular mechanisms of a disorder that results in developmental disabilities and a pathway to search for potential treatments.
COVID-19 vaccine: What’s RNA research got to do with it?
RNA research at the University of Rochester provides an important foundation for developing antiviral drugs, vaccines, and other therapeutics to disrupt the global spread of coronavirus.
Harvey Alter’s Nobel Prize honors a half-century quest
Nobel laureate Harvey Alter’s work as an NIH hematologist led to profound improvements in blood transfusion safety and starkly reduced transmission of a potentially deadly virus.
Unraveling RNA and stereotypes with Lynne Maquat
The Rochester biochemist is best known for unraveling RNA’s role in sickness and in health and for advocating for young women in the sciences.
Study points to new way to slow cancer cell growth
Researchers from the Center for RNA Biology have identified a new way to potentially slow the fast-growing cells that characterize all types of cancer.
Maquat receives Lifetime Achievement Award in Science from International RNA Society
Lynne E. Maquat, the J. Lowell Orbison Endowed Chair and Professor in the Department of Biochemistry and Biophysics at the School of Medicine and Dentistry, has spent her career unraveling what happens in our cells during disease.
Blocking cellular quality control mechanism gives cancer chemotherapy a boost
A University team found a way to make chemotherapy more effective by exposing cancer cells to a molecule that inhibits NMD (nonsense-mediated mRNA decay) prior to treatment with doxorubicin, a drug used to treat leukemia, breast, bone, lung and other cancers.